Liraglutide

About Liraglutide

Liraglutide is a first-generation GLP-1 agonist requiring daily subcutaneous injection. Available as Saxenda® (weight management) and Victoza® (T2D). Largely superseded by weekly tirzepatide and semaglutide.

Manufacturer / source: Novo Nordisk

How it compares

For tirzepatide forms head-to-head, see comparison page. For trial data, see clinical research.

Brand context & FDA status

Liraglutide is the active ingredient in Victoza (FDA-approved 2010 for type 2 diabetes) and Saxenda (FDA-approved 2014 for chronic weight management). It was the first GLP-1 receptor agonist to be approved at higher doses specifically for obesity, and the first to receive a cardiovascular risk reduction indication (Victoza, 2017).

Mechanism of action

Daily-administered GLP-1 receptor agonist with a half-life of approximately 13 hours. Mechanism: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, central appetite suppression via hypothalamic pathways. The albumin-binding moiety reduces renal clearance and extends half-life relative to native GLP-1 (which has a half-life of minutes).

Clinical efficacy data

In type 2 diabetes (Victoza dosing up to 1.8 mg): A1C reduction approximately 1.0–1.5%. LEADER trial (NEJM 2016): 13% reduction in major adverse cardiovascular events. In obesity (Saxenda dosing 3.0 mg): SCALE Obesity and Prediabetes trial showed mean ~8% weight loss at 56 weeks. Magnitude is smaller than newer GLP-1s but historically important as the first established benchmark.

FDA-approved indications

Type 2 diabetes (Victoza), cardiovascular risk reduction in T2D with established CVD (Victoza), and chronic weight management in adults and adolescents 12+ with obesity (Saxenda).

Dosing & titration

Victoza: titrate from 0.6 mg daily to 1.2 mg, max 1.8 mg. Saxenda: titrate weekly from 0.6 mg to 3.0 mg over five weeks. Both are subcutaneous; sites include abdomen, thigh, or upper arm.

Safety profile & adverse events

Most common adverse events: nausea, diarrhea, headache, decreased appetite, vomiting, fatigue. Boxed warning: thyroid C-cell tumor risk. Contraindications: MTC, MEN 2. Monitor: pancreatitis, gallbladder events, hypoglycemia, kidney injury, suicidal ideation (per Saxenda label).

Cost & access in 2026

Victoza approximately $1,000/month; Saxenda approximately $1,350/month. Now less commonly initiated compared with weekly GLP-1s due to the daily-injection burden, though some patients remain on liraglutide successfully.

Frequently asked questions

Is liraglutide effective for diabetes and weight loss?

Yes for both — Victoza is FDA-approved for diabetes (max 1.8 mg) and Saxenda for weight management (3.0 mg). Magnitude of effect is generally smaller than weekly semaglutide or tirzepatide, but it remains a reasonable option in selected patients.

Why are weekly GLP-1s preferred now?

Weekly administration improves adherence and produces stronger pharmacodynamic effects sustained throughout the dosing interval. Newer molecules with engineered half-lives also tend to produce greater absolute weight and A1C reductions.

Can liraglutide be compounded?

Liraglutide compounding has been less common than semaglutide or tirzepatide compounding. The molecule is not currently on the FDA shortage list. Patients seeking compounded GLP-1s should verify pharmacy licensure and FDA standing of any drug substance used.